Navigation Links
Blood-clotting protein modified for people with hard-to-treat hemophilia
Date:5/19/2008

Pathologists at The University of Texas Health Science Center at Houston have developed a chemically modified protein that may help people with a hard-to-treat form of a genetic bleeding disorder known as Hemophilia A. The discovery and the results of pre-clinical tests appear in the May 2 issue of the Journal of Biological Chemistry.

With a shortage of the blood-clotting protein Factor VIII (FVIII), people with Hemophilia A typically receive injections of FVIII derived from plasma or produced synthetically to control potentially life-threatening episodes of bleeding. Unfortunately as many as 1 in 3 people with Hemophilia A produce inhibitor antibodies, which attack the externally-administered FVIII and negate its blood-clotting benefits.

To combat this problem, scientists in the laboratory of Sudhir Paul, Ph.D., at The University of Texas Medical School at Houston, developed a chemically modified version of FVIII which during laboratory tests neutralized these inhibitor antibodies, thus paving the way for the correction of the blood-coagulating process. The modification is called electrophilic FVIII analog (E-FVIII).

Its a two-step process, said Paul, the senior author. The E-FVIII permanently inactivates the antibodies that inhibit blood clotting in 20 to 30 percent of patients receiving Factor VIII replacement therapy. Once the antibodies are cleared, additional FVIII can be injected. The study involved blood donated by eight people with FVIII-resistant Hemophilia A.

Today, people with FVIII-resistant Hemophilia A have limited treatment options, said co-author Keri Smith, Ph.D., an assistant professor of pathology and laboratory medicine at the UT Medical School at Houston. Those options include bypass therapy or multiple FVIII injections. Both are prohibitively expensive and often ineffective to meet emergency blood-clotting needs.

E-FVIII might provide a more economically feasible method of treating inhibitor antibodies, Smith said.

There is no cure for Hemophilia A, and it primarily affects males. About one of every 7,000 males born in the United States has this condition. A person with hemophilia bleeds longer than a person without hemophilia.

Stephanie Planque, who is lead author and is working towards her Ph.D. degree, helped conceive the chemical inactivation principle behind the study. The modified FVIII analog was produced by pathology faculty Hiroaki Taguchi, Ph.D., and Yasuhiro Nishiyama, Ph.D., using newly developed synthesis methods. Miguel Escobar, M.D., of the department of pediatrics and internal medicine at the UT Medical School at Houston and the Gulf States Hemophilia and Thrombophilia Center, led the clinical aspects of the work, and Kathleen Pratt, Ph.D., at the Puget Sound Blood Center and Division of Hematology, University of Washington, Seattle, contributed a genetically-produced protein that helped the study reach its conclusions.

According to Paul, the next step involves clinical trials. E-FVIII is a first generation reagent. Future genetic and chemical manipulations may help develop improved E-FVIII analogs, Paul wrote in the paper.


'/>"/>

Contact: Robert Cahill
Robert.Cahill@uth.tmc.edu
713-500-3030
University of Texas Health Science Center at Houston
Source:Eurekalert

Related medicine news :

1. Draining away brains toxic protein to stop Alzheimers
2. Penn study finds pro-death proteins required to regulate healthy immune function
3. New prion protein discovered by Canadian scientists may offer insight into mad cow disease
4. Emory researchers identify signaling protein for multiple myeloma
5. Human C-reactive protein regulates myeloma tumor cell growth and survival
6. Lowering Blood Protein Wont Help Kidney Patients
7. Blood protein detects lung cancer, even at earliest stage
8. Natural Protein Could Help Spot, Treat Liver Cancer
9. Heat shock proteins are co-opted for cancer
10. How adhesive protein causes malaria
11. Loss of gene leads to protein splicing and buildup of toxic proteins in neurons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... CA (PRWEB) , ... May 23, 2017 , ... By ... season underway in Sonoma County. While officials call for diligence, asking homeowners to scout ... looking at potential health concerns. Along with the annoying buzz of mosquitos is the ...
(Date:5/23/2017)... ... May 23, 2017 , ... New patients from Charleston, ... an experienced dentist practicing in Mt. Pleasant, SC, with or without a referral. A ... for patients with missing teeth in Charleston, SC. Those who suffer from ...
(Date:5/23/2017)... ... , ... Therachat , a smart guided journaling tool for improving mental ... state of anxiety in support of National Mental Health Awareness Month. , The nationwide ... benchmarked general anxiety levels as well as identified the top triggers, impact to regular ...
(Date:5/22/2017)... ... May 22, 2017 , ... ... welcoming new patients with periodontal plastic surgery treatments, including crown lengthening ... Dr. Green provides these esthetic and functional procedures to help patients improve their ...
(Date:5/22/2017)... ... May 22, 2017 , ... Galena, Alaska, has a population of less ... headlines when it was targeted to build a nuclear plant by the TOSHIBA Corporation. ... manager Marvin L. Yoder describes the journey to get power to his small town, ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... , May 22, 2017  As the specialty ... whole continue to make the revolutionary shift from ... important for ensuring positive patient outcomes and shaping ... are shifting focus away from clinical trials and ... of long-term specialty drug therapy utilization in precise ...
(Date:5/15/2017)... , May 15, 2017  Amy Baxter MD, chief ... leader in noninvasive pain relief, was awarded a 2017 ... magazine. Baxter was recognized at the MM&M Top 40 ... York City on May 10, 2017. The ... biopharma industry go "beyond the pill."  "Innovation ...
(Date:5/11/2017)... TORONTO , May 11, 2017  Thornhill ... ) has been awarded an $8,049,024 USD five-year, ... Defense through the Canadian Commercial Corporation (CCC) ( ... Field Anesthesia Systems to administer general anesthesia to ... environment.  "The US Marine Corps have ...
Breaking Medicine Technology: